MS drug safety survey: do patients and doctors know the risks?
NCT ID NCT05301907
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed survey looked at whether healthcare professionals and people with multiple sclerosis (or their caregivers) understand the safety steps needed when using the drug Mayzent (siponimod). Over 300 participants from Europe answered questions about proper use, side effects, and risks. The goal was to see if educational materials are working, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
siponimod (Mayzent)
What this could lead to
If successful, this survey could show that educational materials help patients and doctors use Mayzent more safely, reducing risks like infections or heart issues.
What could go wrong
This is a completed survey, not a treatment trial. It measures knowledge, not health outcomes, so it won't directly improve MS or change how the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Basel, Switzerland